Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Study to Investigate the Efficacy and Safety of Secukinumab (Cosentyx®) 300 mg Administered Subcutaneously in Patients With Active Peripheral Spondyloarthritis (pSpA).

NCT05206591 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05206591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05206591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Study to Investigate the Efficacy and Safety of Secukinumab (Cosentyx®) 300 mg Administered Subcutaneously in Patients With Active Peripheral Spondyloarthritis (pSpA).
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Overall status
Withdrawn
Start date
August 16, 2022
Completion date
June 12, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

active peripheral spondyloarthritis (pspa)